Sydney M Crago

Christina Y. Weng, MD, MBA, shared insights from recent publications on teleretinal screenings for diabetic retinopathy. She will be presenting an overview of these findings at the annual American Academy of Ophthalmology meeting being held in Chicago, Illinois during a talk entitled, "The use of teleretinal screening for diabetic retinopathy."

At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.

In the first five months of the program at Henrietta Johnson Medical Center, 26% of patients with images gradable by EyeArt tested positive for either more-than-mild or vision-threatening diabetic retinopathy.

PMC-403 is a novel TIE2-activating antibody with a mechanism that stabilizes pathological, leaky blood vessels.

Thomas Aaberg, Jr, MD, Neurotech's Chief Medical Officer, shared some insights on the company's recent presentation as well as their upcoming presentations at the annual American Academy of Ophthalmology meeting being held in Chicago, Illinois.

Steven Yeh, MD, discussed his recent presentation at the Retina Society meeting and shared what he is looking forward to presenting at this year's American Academy of Ophthalmology meeting held in Chicago, Illinois.

The annual American Academy of Ophthalmology meeting will include notable data and announcements for many companies in the ophthalmic space as they discuss upcoming and ongoing clinical trials as well as corporate and product developments.

AEYE Health will attend the American Academy of Ophthalmology (AAO) Annual Meeting, from October 18-21 in Chicago.

This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy.

The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024.

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME.

Applied Science, Inc. (ASI) is expanding its AdaptivMD chronic care workflow technology

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

Shruti Sharma, PhD, and a team from the MCG Center for Biotechnology and Genomic Medicine, hope to focus in on a new treatment pathway for diabetic retinopathy.

Everads suprachoroidal delivery technology is designed to enable safe and effective in-office delivery of therapies to the choroidal and retinal tissues via the suprachoroidal space.

The retina space continues to see new advancements and clinical trial results, many of which are shared at industry conferences throughout the year.

David Eichenbaum, MD, spoke with Modern Retina to provide and overview on his presentation at ASRS 2024 and the current state of geographic atrophy treatment.

Dilsher Dhoot, MD, sat down with Modern Retina to provide some insights on the phase 1 HELIOS trial, which he presented on during the 2024 ASRS meeting held in Stockholm, Sweden earlier in 2024.

Prof Bodaghi praises the ingenuity at this year's EURETINA Innovation Spotlight (EIS)

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1.

Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab

Dvey-Aharon is an internationally known AI expert and the inventor of AEYE-DS.

Carl Awh, MD, FASRS, spoke about the presence of members of the American Society of Retina Specialists (ASRS) attending the EURETINA meeting and the value of the international community of retina clinicians connecting at meetings around the globe.

Inflammasome Therapeutics has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug, K9.

Nicole Eter, MD, discussed the use of a magnification implant being used in patients with geographic atrophy (GA) at from this year's EURETINA congress being held in Barcelona, Spain, which took place September 19-22, 2024.

A look back at the 2024 ASRS conference held in Sweden

Yousif Subhi, MD, PhD, delivered the Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC."